On the Cover
New thoughts, therapies for vitiligo August 04, 2016By John JesitusPromising treatments under investigation for vitiligo include afamelanotide, prostaglandin analogues and JAK inhibitors. But don't overlook established treatments such as phototherapy and steroid mini-pulses, an expert says.
In this issue
Biologics, acetaminophen and the multimillion-dollar lawsuitAre doctors liable when patients combine acetaminophen with biologic medications used to treat psoriasis? Are skincare products with probiotics worth the hype?Evidence is mounting for the use of probiotics, prebiotics and microbial lysates in skincare. One expert examines the literature and shares observations.
New target could predict melanoma August 08, 2016By Lisette HiltonNew information could eventually help identify a high-risk population before they get cancer — even prevent skin cancer’s onset. First do no Mohs harm August 08, 2016By Lisette HiltonAn expert advises evaluating each patient’s surrounding circumstances when determining whether Mohs surgery is indicated. New evidence supports combination therapy for metastatic melanoma August 09, 2016By Louise GagnonEvidence-based data about molecular features is evolving to support the use of combination therapy as an option for treating metastatic melanoma. Vismodegib study confirms safety, efficacy for BCC August 09, 2016By John JesitusThe largest-ever vismodegib study in advanced basal cell carcinoma, the STEVIE study, confirms pivotal study findings in a real-world setting, helping dermatologists to provide a complete palette of skin cancer treatments.
Business of Dermatology
One patient’s perspective: Stuck in the middle August 19, 2016By Lisette HiltonDiagnosed at age 22 with psoriasis and psoriatic arthritis, this patient is a widower with three children. She’s on Medicaid. This is her story. Soaring drug costs leave derms, patients scrambling August 19, 2016By Lisette HiltonThe costs of popular drugs—even generics—in dermatology are soaring, leaving patients scrambling for coverage or financial assistance and dermatologists spending precious hours on prior authorizations, drug appeals and reviews. In this first of a five-part series, experts and patients help define the problem.